Med Sci Monit:长期强化生活方式干预可促进III期糖尿病肾病的改善

2020-06-16 MedSci原创 MedSci原创

糖尿病肾病(DN)是糖尿病潜在的致命并发症。虽然生活方式的改变可以降低糖尿病风险,但目前尚不清楚改善生活方式是否可以减缓或逆转DN的进展。本研究评估了通过增加体力活动和减少热量摄入,以减轻体重和炎症为

糖尿病肾病(DN)是糖尿病潜在的致命并发症。虽然生活方式的改变可以降低糖尿病风险,但目前尚不清楚改善生活方式是否可以减缓或逆转DN的进展。本研究评估了通过增加体力活动和减少热量摄入,以减轻体重和炎症为目标的强化生活方式干预(IL-I)是否可以延缓DN的进展。

 

将患者随机分为2组。两组都接受饮食和运动指南,但其中一组(IL-I)比另一组(对照组)接受更频繁的外部支持。我们比较了3个月和6个月时组间代谢和血管健康、氧化还原状态、炎症和肾功能的标志物。代谢和心血管指标包括BMI、血压、血糖化血红蛋白(HbA1c)和血清HDL-胆固醇。通过血清超氧化物歧化酶(SOD)和脂质氧化产物丙二醛(MDA)评估氧化还原状态,而通过血清IL-6和TNF-α浓度评估炎症。肾功能通过尿/血清8-OHdG、白蛋白:肌酐比值(ACR)和肾脏纤维化标志物TGF-β1来评估。

 

结果显示,两组均表现出初始BMI降低,HbA1c降低,HDL-胆固醇升高,但6个月时IL-I组的变化明显较大。6个月后的血压仅IL-I组有所降低。IL-I组还实现了更大的持续SOD增加和MDA降低。最后,只有IL-I组表现出尿ACR、血清/尿8-OHdG和血浆TGF-ß1的显著降低。这些指标在IL-I停止后恶化。

 

总之,该研究结果表明,生活方式的改变,包括运动和饮食,可以延缓肾脏损害,促进DN的改善。

 

原始出处:

 

Li Dong, Jie Li, et al., Long-Term Intensive Lifestyle Intervention Promotes Improvement of Stage III Diabetic Nephropathy. Med Sci Monit. 2019 Apr 25;25:3061-3068. doi: 10.12659/MSM.913512.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085122, encodeId=7ff020851224b, content=<a href='/topic/show?id=0fcf9604fd' target=_blank style='color:#2F92EE;'>#II期糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9604, encryptionId=0fcf9604fd, topicName=II期糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sun Jun 28 14:26:19 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916287, encodeId=9488191628e51, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 19 15:26:19 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594756, encodeId=f8251594e564e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610528, encodeId=0e75161052885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043163, encodeId=6ec7104316305, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 18:26:19 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085122, encodeId=7ff020851224b, content=<a href='/topic/show?id=0fcf9604fd' target=_blank style='color:#2F92EE;'>#II期糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9604, encryptionId=0fcf9604fd, topicName=II期糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sun Jun 28 14:26:19 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916287, encodeId=9488191628e51, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 19 15:26:19 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594756, encodeId=f8251594e564e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610528, encodeId=0e75161052885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043163, encodeId=6ec7104316305, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 18:26:19 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2020-11-19 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085122, encodeId=7ff020851224b, content=<a href='/topic/show?id=0fcf9604fd' target=_blank style='color:#2F92EE;'>#II期糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9604, encryptionId=0fcf9604fd, topicName=II期糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sun Jun 28 14:26:19 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916287, encodeId=9488191628e51, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 19 15:26:19 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594756, encodeId=f8251594e564e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610528, encodeId=0e75161052885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043163, encodeId=6ec7104316305, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 18:26:19 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085122, encodeId=7ff020851224b, content=<a href='/topic/show?id=0fcf9604fd' target=_blank style='color:#2F92EE;'>#II期糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9604, encryptionId=0fcf9604fd, topicName=II期糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sun Jun 28 14:26:19 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916287, encodeId=9488191628e51, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 19 15:26:19 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594756, encodeId=f8251594e564e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610528, encodeId=0e75161052885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043163, encodeId=6ec7104316305, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 18:26:19 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2085122, encodeId=7ff020851224b, content=<a href='/topic/show?id=0fcf9604fd' target=_blank style='color:#2F92EE;'>#II期糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9604, encryptionId=0fcf9604fd, topicName=II期糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sun Jun 28 14:26:19 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916287, encodeId=9488191628e51, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Nov 19 15:26:19 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594756, encodeId=f8251594e564e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610528, encodeId=0e75161052885, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 18 06:26:19 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043163, encodeId=6ec7104316305, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jun 16 18:26:19 CST 2020, time=2020-06-16, status=1, ipAttribution=)]
    2020-06-16 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

汪年松教授:糖尿病肾病的发病机制及临床转化丨CSN2019

在前面CSN2019大会糖尿病肾病专题内容分享中,我们为大家介绍了“DKD发病机理研究与药物治疗靶点探索”和“延缓糖尿病肾病进展的治疗策略”,了解了关于糖尿病肾病(DN)的治疗。那么,除了可以用药物治疗和生活方式干预来延缓糖尿病肾病疾病进展,能不能对糖尿病肾病进行早期筛查和预防呢?上海交通大学附属第六人民医院肾脏科主任汪年松教授结合目前精准医疗的发展和早期敏感生物标记物的研究,为我们介绍了糖尿病肾

Oxid Med Cell Longev:糖尿病肾病患者细胞衰老的信号

糖尿病肾病是西方国家慢性肾脏病(CKD)的主要原因。值得注意的是,它在中国的发病率迅速上升。心血管疾病和神经系统疾病是常见的并发症,也是患者进展为终末期肾病(ESRD)和死亡的高危风险。然而,糖尿病肾

孙林教授:延缓糖尿病肾病进展的治疗策略丨CSN2019

糖尿病肾病(DN)是糖尿病(DM)的主要并发症,也是国内外导致终末期肾脏病(ESRD)的主要原因,严重危害人类健康。在9.20日正在进行的中华医学会肾脏病学分会2019年学术年会糖尿病肾病专场中,中南大学湘雅二医院孙林教授为我们详细介绍了关于延缓糖尿病肾病进展的治疗策略的相关内容。 孙林教授指出,DN患者一旦进入临床大量蛋白尿期,治疗就十分有限,因此延缓DN进展是治疗DN的重要措施。

喜鹊医药研发的糖尿病肾病创新药硝酮嗪进入临床2期

广州喜鹊医药有限公司(以下简称“喜鹊医药”)创新药物硝酮嗪治疗糖尿病肾病II期临床研究于2019年11月26日在北京同仁医院顺利启动。启动会由创新药物硝酮嗪治疗糖尿病肾病II期临床研究组组长, 北京同仁医院内分泌科主任, 北京市糖尿病研究所所长,北京学者杨金奎教授主持。该临床II期研究的主要目的是评价硝酮嗪在糖尿病肾病患者中的有效性和安全性。 杨金奎教授表示,“虽然近年来糖尿病肾病的

Diabetes Metab Syndr:补充维生素D 3对糖尿病性肾病患者的影响

众所周知,糖尿病肾病是肾脏和心血管疾病进展的独立危险因素。由于维生素D缺乏与糖尿病肾病有关,糖尿病肾病人群中维生素D缺乏,本研究探究了维生素D3对糖尿病肾病患者代谢和炎症参数的影响。

2019年梅斯医盘点:糖尿病肾病研究进展

糖尿病肾病(DKD)是由糖尿病引起的肾脏损害,是导致终末期肾病的主要原因,已成为全球公共卫生问题。 DKD的临床分期及评价指标 通常,我们可将DKD分为5期,从Ⅱ期开始就出现微量蛋白尿。目前,有关DKD进展的研究所采用的评价指标包括:蛋白尿的变化、肌酐水平或GFR的变化或是肾损伤硬终点(即由于肾脏疾病导致的死亡和/或ESRD)。 纵观DKD的发展过程,根据DKD自然病